- Investing Ideas
- Hong Kong Healthcare Undervalued based on future growth
Hong Kong Healthcare Undervalued based on future growth
Results
7
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
7 companies
Sinopharm Group
Market Cap: HK$54.5b
Engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People’s Republic of China.
1099
HK$17.35
7D
0.6%
1Y
-8.2%
Zylox-Tonbridge Medical Technology
Market Cap: HK$6.1b
A medical device company, provides neuro- and peripheral-vascular interventional medical devices in the People’s Republic of China and internationally.
2190
HK$18.04
7D
-5.9%
1Y
-22.7%
Beijing Chunlizhengda Medical Instruments
Market Cap: HK$5.7b
Engages in the research, development, production, and sale of surgical implants, instruments, and related products in the People’s Republic of China and internationally.
1858
HK$9.35
7D
4.0%
1Y
-40.1%
LEPU ScienTech Medical Technology (Shanghai)
Market Cap: HK$3.8b
An investment holding company, engages in the manufacture and sale of interventional treatment series occluders and heart valve medical devices.
2291
HK$11.11
7D
-19.0%
1Y
-59.2%
Chaoju Eye Care Holdings
Market Cap: HK$1.8b
Owns and operates a network of ophthalmic hospitals and centers in the People’s Republic of China.
2219
HK$2.60
7D
-3.0%
1Y
-12.5%
Yonghe Medical Group
Market Cap: HK$1.2b
Provides hair-related healthcare services in China.
2279
HK$2.38
7D
8.2%
1Y
-16.8%
Sisram Medical
Market Cap: HK$1.2b
Engages in the research, design, development, manufacture, sale, and marketing of medical aesthetics and dental equipment, home-use devices, injectables, and cosmeceutical products in the Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America.
1696
HK$2.32
7D
-5.3%
1Y
-61.8%